abstract: Body contouring following massive @entity353 (MWL) has gained in popularity. The demand for upper arm contouring procedures has increased, and we elected to evaluate our results, complications, and @entity1 satisfaction with brachioplasty techniques in MWL @entity1 . A retrospective review was performed on all @entity1 who underwent a brachioplasty procedure. @entity1 demographics and risk factors were queried. We evaluated surgical techniques and outcomes. Thirty-one @entity1 underwent a bilateral brachioplasty, with an average follow-up of 16 months. The surgical technique included double @entity7085 n = 16, and L-shaped n = 15. The average @entity353 before the procedure was 146 pounds, and the average body mass index at the time of the surgery was 30. Risk factors were present in 68% of the @entity1 . The complication rate was 22%, including cellulitis, @entity1410 , @entity281 , @entity245 , and lymphocele. The revision rate was 16%, most being minor scar revisions for contour improvement. @entity1 satisfaction scores included overall satisfaction 4.3/5, contour improvement 4.3/5, symptomatic improvement 4.9/5, and scar appearance 3.9/5. Most @entity1 (94%) reported improved self-esteem, 94% being more comfortable wearing short sleeve shirts, and 94% would undergo the procedure again. Brachioplasty is a relatively safe and effective procedure for upper body contouring in the MWL @entity1 . Complications are minor, and small revisions in contour are not uncommon. @entity1 report improvement in contour and self-esteem, and a high level of satisfaction with this procedure, despite the potential for an unfavorable scar.

title: An outcome analysis of brachioplasty techniques following massive XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Patient']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['delayed healing']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity353 :: (MESH:D015431,Disease) :: ['weight loss']


abstract: Raw starch granules of mature mungbean ( @entity2773 L. cv. KPS1) seeds were prepared by two methods into crude and @entity6928 ( @entity6928 )-washed forms. The purity, shape, size distribution, and associated protein profiles were examined. The appearance of raw starch granules showed a bimodal type distribution in which average granules had typical ovoid shapes, whereas the small ones were spherical. Abnormal granule surface with distinct @entity5 -like or dented hole features were also observed in raw starch granules. @entity6928 -washed granules had a smooth surface compared to that of the crude form. The granule size distribution ranged from 6-35  m; most 15-25  m (   53%), followed by 25-35  m (   26%). Small granules (<15  m) amounted to    18%, and granules >35  m consisted of    3%. The two forms were further refined by trichloroacetic ( @entity2974 ) treatment to reveal surface proteins on the crude granules or tightly bound proteins on @entity6928 -washed granules. In the washed-refined granules, only a few integral proteins were retained. The major 58-kDa protein was identified to be granule-bound starch synthase I by sequence homology with that in @entity11314 ( @entity11314 ) and @entity2829 ( @entity2829 ) using MALDI-TOF mass and Mascot search.

title: Morphology, associated protein analysis, and identification of 58-kDa starch synthase in mungbean ( XXXX L. cv. KPS1) starch granule preparations.

entities_list: @entity6928 :: ('MESH:C028019', 'Chemical') :: ['cesium chloride', 'CsCl']

entities_list: @entity11314 :: ('3917', 'Species') :: ['Vigna unguiculata', 'cowpea']

answer: @entity2773 :: (157791,Species) :: ['Vigna radiata']


abstract: Treatment of @entity1211 ( @entity1211 ) usually starts with concomitant administration of heparin or low-molecular-weight heparin (LMWH) and a @entity2067 antagonist. The parenteral anticoagulant, which is given for at least 5 days, is stopped once the @entity2067 antagonist produces a therapeutic level of anticoagulation. Although the introduction of LMWH has simplified the initial treatment of @entity1211 , problems remain. LMWH must be given by daily subcutaneous (SC) injection and @entity2067 antagonists require routine coagulation monitoring, which is inconvenient for @entity1 and physicians. Recently, 3 new anticoagulants have been introduced in an attempt to overcome these limitations. These include fondaparinux and idraparinux, synthetic analogs of the pentasaccharide sequence that mediates the interaction of heparin and LMWH with @entity5582 , and @entity24772 , an orally active inhibitor of thrombin. These agents produce a predictable anticoagulant response; thus, routine coagulation monitoring is unnecessary. Because they do not bind to platelets or platelet factor 4, fondaparinux and idraparinux do not cause @entity882 ( @entity882 ). Unlike @entity2067 antagonists, @entity24772 has a rapid onset of action, thereby obviating the need for concomitant administration of a parenteral anticoagulant when starting treatment. The lack of an antidote for these new agents is a drawback, particularly for idraparinux, which has a long half-life.

title: New anticoagulants for treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['HIT', 'heparin-induced thrombocytopenia']

entities_list: @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism']

entities_list: @entity24772 :: ('MESH:C426686', 'Chemical') :: ['ximelagatran']

answer: @entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']


abstract: Little is known about low-grade @entity816 with @entity6831 at diagnosis. A review of medical records identified this phenomenon in eight of 150 pediatric @entity1 evaluated between 1985 and 1994 for histologically confirmed low-grade @entity816 . These @entity1 (five male and three female) ranged in age from 5 months to 20 years (median 8 years). Symptoms of @entity66 were minimal or absent. Primary @entity5 sites were the hypothalamus in four cases, brainstem/spinal cord in three, and temporal lobe in one. Patterns of dissemination (evaluated by computerized tomography and/or magnetic resonance imaging techniques) appeared to be related to the primary site: @entity2339 metastasized along the ventricular cerebrospinal fluid pathways, and @entity5 in other locations disseminated along subarachnoid pathways. Following initial treatment with chemotherapy (in three), partial resection (in one), radiation therapy (in three), and chemotherapy plus irradiation (in one), four @entity1 required salvage therapy for progressive or recurrent disease. Seven of the eight @entity1 are alive with stable or progressive disease 6 to 105 months postdiagnosis (median 15 months). Low-grade @entity816 with @entity6831 is responsive to chemotherapy and radiation, a proportion showing periods of stable disease. The optimum therapy or combination of therapies remains unclear.

title: Low-grade @entity816 with XXXX at diagnosis.

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['neuraxis disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity6831 :: ('MESH:D004673', 'Disease') :: ['initial neuraxis dissemination', 'neuraxis dissemination']

entities_list: @entity2339 :: ('MESH:D007029', 'Disease') :: ['hypothalamic tumors']

entities_list: @entity816 :: ('MESH:D001254', 'Disease') :: ['astrocytoma']

answer: @entity6831 :: (MESH:D004673,Disease) :: ['neuraxis dissemination']


abstract: OBJECTIVE: To evaluate retrospectively the importance of invasion beyond the basement membrane on overall survival in @entity6887 and its influence on the necessity of postoperative adjuvant therapy (stage 0 vs. stage I). DESIGN: In a nationwide analysis the data of 51 @entity1 were evaluated. The participating departments provided the study center with histologic specimens. A re-staging was done according to the FIGO-classification for @entity6887 . Stage 0 @entity1 received no further postoperative therapy, in stage I @entity1 were divided in 2 groups to evaluate the impact of postoperative adjuvant therapy (chemotherapy vs. irradiation). RESULTS: @entity1 of stage 0 had a significantly better prognosis than @entity1 of stage I (p = 0.035). Stage I @entity1 treated by irradiation showed a significantly better prognosis than @entity1 treated by chemotherapy (p = 0.017). CONCLUSION: Tumour penetration through the basement membrane causes prognosis to deteriorate significantly (5-year survival rate about 50% in stage I). Postoperative therapy is thus indicated with stage I disease. Irradiation seems to give better results than chemotherapy.

title: XXXX --a retrospective survey of 51 cases. Austrian Cooperative Study Group for @entity6887 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity6887 :: ('MESH:D005185', 'Disease') :: ['Fallopian tube carcinoma', 'Fallopian tube carcinomas']

answer: @entity6887 :: (MESH:D005185,Disease) :: ['Primary fallopian tube carcinoma']


abstract: UNASSIGNED: 5149 Background: It is difficult to assess a @entity1 's quality of life (QOL) and mood status during a busy clinic, yet QOL can influence the decision to continue therapy, especially during palliation. The objective of this study was to determine how standardized tools for @entity308 screening and QOL assessment could be integrated in a routine clinic visit. METHOD: @entity1 with @entity5 completed a QOL assessment with a 100 mm LASA scale and the Karnofsky performance status prior to three consecutive clinic visits for chemotherapy. Before the 2nd and 3rd visit they also completed the Functional Assessment of Cancer Therapy (FACT-G) and Center for @entity308 (CES-D) scale. After each visit questions about @entity1 satisfaction were answered on a 5 point Lickert scale and the physician completed the LASA scale and the Karnofsky performance status assessment. After the 3rd visit the physician viewed the FACT-G and CES-D results and discussed them with the @entity1 . Descriptive statistics and t-test were used for evaluation. RESULTS: 25 @entity1 completed all three assessments, 22 were treated for recurrent disease. The mean LASA scale values as rated the @entity1 at the first second and third clinic visit respectively were 68, 71 and 76; values determined by the physician were 73, 74 and 77; the most similar assessment by the @entity1 and physician occurred after the third visit. The mean FACT-G score was 75 before the 2nd and 78 before the 3rd visit. The mean CES-D score was 19 before the 2nd and 17 before the 3rd visit. After the 2nd visit 18 @entity1 felt that answering the questions made them more aware of their QOL; 20 @entity1 reported feeling this way after the 3rd visit. Four @entity1 did not like completing the questionnaires. @entity1 felt their needs were addressed with a score of 4.76 after the 1st and 4.96 after the 3rd visit (p=0.01); the score regarding @entity1 satisfaction increased from 4.43 to 4.69 (p= 0.04). The average time needed for answering all questions was 9 minutes. CONCLUSION: It is possible to integrate quality of life assessment with the FACT-G and @entity308 screening with the CES-D into a routine oncology clinic visit. No significant financial relationships to disclose.

title: Quality of life assessment and XXXX screening in the gynecologic oncology clinic.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Epidemiologic-Depression', 'depression']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['gynecologic cancers']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depression']


abstract: BACKGROUND AND AIMS OF THE STUDY: A number of studies have pointed out that parenting style has a longstanding impact on @entity458 . Besides parental/familial risk factors certain aspects of the parent-adolescent relationship may serve as a protective factor and help prevent @entity308 such as the authoritative parenting style. The aim of the present study has been to analyze interrelationships between adolescent depressive symptomatology, authoritative parenting style, negative and positive parental links. METHOD: The study was carried out on in all primary and secondary schools in Mako and the surrounding region in the spring of 2010, students of grades 7-12 (N = 2072), 49.2% of the sample were males and 50.8% females; 38.1% primary school pupils and 61.9% high school students. Self-administered questionnaires @entity308 ( @entity6659 ) and parental variables beyond sociodemographics. After descripive statistics, correlation and multiple linear regression analyses have been used to detect interrelationships. RESULTS: Data support the protective effect of authoritative parenting style in relation to @entity308 , particularly among @entity1 . Among @entity1 , only mother's responsive behavior proved to be a protective factor. Among @entity1 , however, both elements of the father's authoritative parenting style were decisive; not only responsiveness but also demandingness. The parenting style of the opposite-sex parent was prevailing in both sexes. Negative family interactions served as a risk factor, whereas positive parental identification was a protective factor during adolescence as well. CONCLUSION: There is a need to strengthen the role of the authoritative parenting style and to guarantee the presence of the opposite-sex parents in the adolescents' lives. Nowadays there are family-oriented interventions which put forward the effectiveness of parenting and problem-solving and aiming at harmonizing the parent-adolescent relationship.

title: [Control or involvement? Relationship between parenting style and XXXX ].

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['adolescent depression', 'contained items of measuring depressive symptoms']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological health']

answer: @entity308 :: (MESH:D003866,Disease) :: ['adolescent depression']


abstract: Background: House dust mites are important airborne allergens worldwide, particularly in the tropical environment. Objective: To assess sensitization of @entity56 @entity1 to different mite species in the Cuban city of Camaguey; as well as to compare standardized allergen extracts from different sources by skin prick tests. @entity1 and method: Skin prick tests were performed in 60 @entity1 with @entity565 and/or @entity2023 and in 60 non- @entity56 volunteers, ranging from 2 to 76 years old. In both groups, Diater-Prick lancets were used, together with Valergen extracts (Biocen, Cuba) at 20,000 BU/mL and Diater extracts (Argentina) at 50,000 UBE/PNU/mL. Results: The highest values of sensitization prevalence using Diater extracts were seen in @entity7130 (Dp), @entity8786 (Df), and Blomia tropicalis (Bt) in @entity56 @entity1 and in non- @entity56 controls. Diagnostic sensitivity values were: Dp, 79; Df, 84; Bt, 84 and B. kulagini, 83%. Specificity varied from 72 to 85%. On the other hand, with Biocen extracts, the highest positivity was noted in Dp and D. siboney (Ds). Sensitivity values were 78% (Dp); 78% (Ds) and 82% (BT). Specificity values ranged from 79 to 82%. Conclusions: The standardized allergen extracts from the assessed laboratories induced similar values of sensitivity and specificity.

title: [Skin prick tests with standardized extracts of mites of different precedence in @entity1 with @entity565 and XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['allergic rhinitis']

entities_list: @entity7130 :: ('6956', 'Species') :: ['Dermatophagoides pteronyssinus']

entities_list: @entity8786 :: ('6954', 'Species') :: ['Dermatophagoides farinae']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

answer: @entity2023 :: (MESH:D006255,Disease) :: ['allergic rhinitis']


abstract: The main principle for treatment of @entity1171 is @entity4142 reduction until bony union is achieved. Old fractures of the ankle with residual @entity6877 , however, may cause persistent @entity158 , @entity1143 , and range-of-motion limitation, and make eventual ankle arthrodesis inevitable. Restoration of the integrity of the ankle mortise is the determining factor for successful repair of this type of @entity1171 . Old @entity1171 , where malunion has already occurred, is a great challenge for the orthopedic surgeon. Twelve such @entity1 were treated by means of reconstructive @entity5588 without bone graft at the authors' institution from 1997 to 1999. These @entity1 had persistent symptoms and radiographic evidence of a fibula that had healed in a shortened, rotated position, resulting in widening of the ankle mortise. The average time interval between injury and reconstructive operation was 18 months. At follow-up, which averaged 34 months, greatly improved ambulation and level of joint function was noted for all @entity1 , and follow-up x-ray confirmed good ankle mortise geometry. The short-term results for these @entity1 were good, with further follow-up planned to determine efficacy long term. In conclusion, reconstructive @entity5588 is a worthwhile procedure for old @entity1171 with malunion, and it can also postpone degenerative change in the ankle joint.

title: @entity5588 without bone graft for old XXXX with residual @entity6877 .

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['joint effusion']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1171 :: ('MESH:D064386', 'Disease') :: ['ankle fracture', 'ankle fractures']

entities_list: @entity6877 :: ('MESH:D046548', 'Disease') :: ['diastasis']

entities_list: @entity5588 :: ('MESH:C538010', 'Disease') :: ['corrective-elongation osteotomy']

answer: @entity1171 :: (MESH:D064386,Disease) :: ['ankle fracture']


abstract: The ability of @entity0 to synthesize hormones is well recognized, and local production of sex @entity230 is thought to play a role in @entity0 growth. We measured the intratumour and circulating levels of @entity251 , @entity586 ( @entity587 ) and @entity53 in 35 histologically confirmed @entity3909 mammary tissues obtained at breast surgery from 34 postmenopausal @entity1 , age 50-85 years. Intra-tissue @entity230 were extracted with @entity1068 : @entity1324 (1:1; v/v), defatted with 70% @entity1042 in water, and extracted with ether. @entity230 , from tissue and serum, were separated by partition chromatography on celite columns and were measured by RIA. Intratumour @entity251 and @entity587 concentrations were significantly correlated, after the exclusion of an outlier (rs = 0.71; P = 0.0001). No association was found between @entity53 and either of the two @entity3800 . Mean @entity53 and @entity587 concentrations were significantly higher in tissue than in blood (P = 0.0001). Mean @entity251 levels in tissues did not significantly differ from those measured in blood. Our data suggest that at least a part of intratissue @entity587 is produced locally from @entity251 . The meaning of high @entity53 and @entity587 levels in @entity5 tissue still needs to be defined.

title: @entity251 , XXXX and @entity53 levels in postmenopausal @entity0 tissues.

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast tumours', 'breast cancer']

entities_list: @entity586 :: ('MESH:D013196', 'Chemical') :: ['dihydrotestosterone']

entities_list: @entity1042 :: ('MESH:D000432', 'Chemical') :: ['methanol']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity3909 :: ('MESH:D055756', 'Disease') :: ['carcinomatous']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['oestradiol']

entities_list: @entity3800 :: ('MESH:D000728', 'Chemical') :: ['androgens']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['Steroids', 'steroids']

answer: @entity586 :: (MESH:D013196,Chemical) :: ['dihydrotestosterone']


abstract: INTRODUCTION: Electronic cigarette (EC) use is growing dramatically with use highest among young adults and current smokers. One of the most common reasons for using ECs is interest in quitting or reducing cigarettes per day (CPD); however there are few @entity23 ( @entity23 ) on the effect of ECs on smoking abstinence and reduction. METHODS: We conducted a two-arm; double-blind @entity23 . Subjects were randomized to receive 3-weeks of either disposable 4.5% @entity1239 EC (intervention) or placebo EC. The primary outcome was self-reported reduction of at least 50% in the number of @entity9047 smoked at week 3 (end of treatment) compared to baseline. Study subjects (n = 99) were young adult (21-35), current smokers (smoked >=  10 @entity9047 ) living in NYC. RESULTS: Compared with baseline, a significant reduction in @entity9047 was observed at both study time periods (1 and 3 weeks) for intervention (P < .001) and placebo (P < .001) groups. Between-group analyses showed significantly fewer @entity9047 in the intervention group compared to the placebo group at week 3 (P = .03), but not at any other follow-up periods. The logistic regression analysis showed that using a greater number of ECs, treatment condition and higher baseline readiness to quit were significantly associated with achieving at least 50% reduction in @entity9047 at the end of treatment. CONCLUSION: A diverse young adult sample of current everyday smokers, who were not ready to quit, was able to reduce smoking with the help of ECs. Further study is needed to establish the role of both placebo and @entity1239 containing ECs in increasing both reduction and subsequent cessation. IMPLICATIONS: Despite the critical need for well-designed clinical trials on the effect of ECs on cessation and cigarette reduction, the majority of studies have been observational or noncomparative intervention designs. Only three RCTs studying ECs as a cessation or reduction intervention have been published, and none were conducted in the United States. The current study adds knowledge to current literature on the feasibility of using ECs to aid smoking reduction among young smokers in US urban populations.

title: A Randomized Trial Comparing the Effect of XXXX Versus Placebo Electronic Cigarettes on Smoking Reduction Among Young Adult Smokers.

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['randomized controlled trials', 'RCT']

entities_list: @entity1239 :: ('MESH:D009538', 'Chemical') :: ['nicotine']

answer: @entity1239 :: (MESH:D009538,Chemical) :: ['Nicotine']


abstract: PURPOSE: Discuss the place of radiotherapy given in a curative intent in elderly @entity1 with @entity263 according to complications, local control, survival observed in a specific and a review of the literature. @entity1 AND METHODS: The cohort consisted of 65 males aged 80 or more with @entity263 who choose radiotherapy as a curative modality. Twelve radiotherapy centres affiliated to the Rare @entity5 Network participated to the study. The retrospective analysis was carried out on immediate and late side-effects, biological free of relapse survival and global survival. Multivariate analysis took into account the comorbidities, the initial prostatic specific antigen (PSA) value, the Gleason score and the therapeutic modalities. RESULTS: From January 1990 to December 2000, 65 @entity1 were included into the cohort. Mean age was 81 years. The specific series consisted of 10 T1, 40 T2 and 15 T3 N0M0. Median follow up was 65 months. Immediate and late complications were comparable to those described in younger @entity1 who received a similar irradiation. There were no negative impact of the treatment on disease free survival and global survival. Recent literature did suggest analogous results. CONCLUSIONS: Radiation therapy with a curative intent should not be systematically withheld in elderly @entity1 with @entity263 .

title: [ XXXX : what role for curative radiotherapy in elderly?].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['localised prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

answer: @entity263 :: (MESH:D011471,Disease) :: ['Prostate cancer']


abstract: PURPOSE: @entity1 with @entity3762 ( @entity3762 ) often present with interictal @entity11228 ( @entity11228 ) at rest (spontaneous @entity11228 ), during @entity10441 , and in response to photic stimulation (photoparoxysmal response or @entity11595 ). @entity1092 ( @entity2052 ) is a first-line antiepileptic drug for therapy of @entity1 with @entity3762 . Herein we investigated the effect of @entity2052 on all three types of @entity11228 in @entity1 and adolescents with @entity3762 . METHODS: Routine electroencephalography (EEG) during wakefulness, which was recorded before @entity2052 monotherapy and up to four times during the first year of the @entity2052 treatment, was analyzed retrospectively. For the analysis of the @entity2052 effect on spontaneous @entity11228 and @entity11228 under @entity10441 , the number and duration of @entity11228 were counted. @entity11228 under intermittent photo stimulation (IPS) were classified according to the extent of propagation (grading). Response to @entity2052 treatment (rest/ @entity10441 ) was defined as a disappearance of @entity11228 within the year after @entity2052 introduction. KEY FINDINGS: Eighty-four @entity1 (37 male and 47 female, mean age 9.5        4.1 years) exhibited spontaneous @entity11228 or @entity11228 under @entity10441 . From this sample, 34 @entity1 exhibited the @entity11595 (7 male and 27 female, mean age 10.1        3.9   years). A significant reduction in the number and duration of spontaneous @entity11228 and @entity11228 under @entity10441 was observed in the first 6 weeks of treatment (p    <=   0.001, corrected, 87.3% responders). This effect remained stable over the 1 year observation period. Concerning @entity11595 , only 4 (12.9%) of 31 @entity1 were classified as responders. The difference between groups of @entity1 with spontaneous/induced @entity11228 and @entity11595 according to the number of responders was significant (p<0.001). SIGNIFICANCE: This study provides evidence that the effect of @entity2052 on @entity11228 differs dependent on the types of @entity11228 . In the majority of @entity1 , spontaneous @entity11228 and @entity11228 induced by @entity10441 disappeared, whereas the @entity11595 mostly remained under @entity2052 treatment. These results point to different pathogenetic mechanisms underlying the spontaneous and the evoked generalized @entity302 activity in the EEG.

title: XXXX reduces spontaneous generalized spikes and waves but not photoparoxysmal reactions in @entity1 with @entity3762 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients']

entities_list: @entity1092 :: ('MESH:D014635', 'Chemical') :: ['Valproic acid']

entities_list: @entity11228 :: ('MESH:C535500', 'Disease') :: ['SWDs', 'spike-wave discharges']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic']

entities_list: @entity3762 :: ('MESH:C562694', 'Disease') :: ['idiopathic generalized epilepsies', 'IGEs', 'IGE']

entities_list: @entity10441 :: ('MESH:D006985', 'Disease') :: ['hyperventilation']

answer: @entity1092 :: (MESH:D014635,Chemical) :: ['Valproate']


abstract: BACKGROUND: Recently, endoscopic surgery for small superficial @entity356 has become increasingly more challenging, and the treatment criteria remain controversial. METHODS: To examine the metastatic potential of intramucosal @entity356 (IMGCs), IMGCs with regional lymph node involvement (NI) were compared with IMGCs without regional lymph NI clinicopathologically. To clarify the metastatic behavior of well differentiated @entity420 (W-type), immunohistochemical staining using Ki-67 and @entity1364 ( @entity1364 ) monoclonal antibodies were performed. RESULTS: Of the 943 lesions with IMGC, 21 (2.2%) were NI on histologic examination. There was no significant difference between the macroscopic classification and the incidence of NI. The sizes of the IMGCs with NI (median, 4.3 cm) were significantly larger than the IMGCs without NI (median, 2.4 cm). Among the histologic grades classified according to the predominant features, the incidence of NI in poorly differentiated @entity420 (P-type) (12/304, 3.9%) was significantly higher than that in well differentiated (W-type) (6/489, 1.2%). Besides the 12 P-type IMGCs, 6 well and moderately differentiated type IMGCs contained some poorly differentiated components, totaling 18 IMGCs (86%) that were either mainly or partially P-type. Among the W-type IMGCs, the mean values of the Ki-67 and @entity1364 labeling indices (LI) for IMGCs with NI (Ki-67, 47.5%; @entity1364 , 58.3%) were higher than those of the 25 randomly selected IMGCs without NI (Ki-67, 39.2%; @entity1364 , 39.9%). CONCLUSIONS: The potential for NI in IMGCs seems to be related closely to @entity5 size, the presence of poorly differentiated components, and, particularly in the W-type IMGC, the LI that are demonstrated immunohistochemically with Ki-67 and/or @entity1364 .

title: Metastasizing XXXX . Well differentiated type and proliferative activity using proliferative cell nuclear antigen and Ki-67.

entities_list: @entity1364 :: ('5111', 'Gene') :: ['proliferating cell nuclear antigen', 'PCNA']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancers', 'gastric carcinomas']

answer: @entity356 :: (MESH:D013274,Disease) :: ['intramucosal gastric carcinomas']


abstract: OBJECTIVE: This study aimed to estimate the efficacy and tolerability of the combination of @entity3591 and @entity1289 inhibitors as compared with @entity3591 monotherapy in the treatment of @entity101 . METHODS: The Cochrane Central Register of Controlled Trials, PubMed, and Embase were searched for relevant articles. A random effect model of meta-analysis was used for the selected randomized controlled trials (RCTs). RESULTS: A total of 17 randomized controlled trials involving 3291 @entity1 were identified using predefined criteria. The combination treatment of @entity3591 and @entity1289 inhibitors resulted in a greater reduction of both systolic blood pressure (SBP) [ @entity353 ( @entity353 ) 5.72, 95% CI: (confidence interval) 4.10-7.33] and diastolic blood pressure (DBP) ( @entity353 3.62, 95% CI: 4.85-2.39) than monotherapy. The combination treatment also generated significantly greater reductions for the mean ambulatory SBP and @entity11559 during the full 24 hours ( @entity353 : SBP 4.24, 95% CI: 6.82-1.67; DBP 2.23, 95% CI: 3.73-0.69), but not for the trough ( @entity353 : SBP 4.52, 9.56 to -0.51; DBP 3.7, 7.65 to -0.25). The @entity101 therapeutic control (SPB <140, DBP <90 mmHg) rate for the combination treatment is higher than that for monotherapy [relative risk (RR): 1.36, 95% CI: 1.07-1.73]. The combination treatment also resulted in a lower overall rate of adverse events (RR: 0.86, 95% CI: 0.75-0.99) and @entity4 (RR: 0.40, 95% CI: 0.29-0.56), but a higher rate of cough (RR: 3.28, 95% CI: 2.03-5.29) as compared with monotherapy. CONCLUSION: This meta-analysis suggests that the combination treatment provides superior BP control, fewer adverse events, and better tolerability in @entity101 @entity1 than monotherapy. Further research should explore the mechanism of the combination therapy and whether it is associated with the reduction of @entity65 morbidity and mortality.

title: @entity3591 and @entity1289 inhibitor combination versus XXXX monotherapy in @entity101 : a meta-analysis of randomized controlled trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['angiotensin-converting enzyme']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['WMD', 'weighted mean difference']

entities_list: @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity3591 :: (MESH:D017311,Chemical) :: ['amlodipine']


abstract: OBJECTIVES: To provide valid clinical data of early in-hospital @entity204 with presumed @entity583 ( @entity583 ) who are often not included in clinical trials or registries. METHODS: From August 2004 to August 2006 all @entity1 (age 25-84 years) dying within 24 h after hospitalization in a large tertiary care academic teaching hospital were screened regarding an underlying cardiovascular cause of @entity204 . RESULTS: After validation, 79 out of 1,352 @entity1 remained with a final diagnosis of @entity583 . Sixty-six percent of these experienced prehospital @entity1167 or @entity1457 . In 37% no resuscitation attempts were performed in-hospital, the most common reason being multimorbidity. Only 23% could be transferred to coronary angiography for revascularisation attempts. An independent panel of clinicians judged that only in one @entity1 would another management strategy have been promising. Of interest, 33% of the deceased @entity1 had typical or atypical @entity662 the days before the lethal event. CONCLUSION: A large percentage of @entity583 @entity1 who died soon after hospitalization were in critical circulatory state directly before hospitalization. In 37%, in-hospital resuscitation attempts were omitted for understandable reasons. Options for improvement in acute care in the investigated setting were not found. However, in one third of the cases earlier preventive measures might have been reasonable.

title: Are there options to prevent early occurring XXXX in @entity583 : prospective evaluation of all <24 h in-hospital @entity204 , 2004-2006--the MONICA/KORA Augsburg Infarction Registry.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

answer: @entity204 :: (MESH:D003643,Disease) :: ['deaths']


abstract: The application of recombinant DNA techniques has identified two fundamental mechanisms of tumorigenesis in @entity1 . The first involves a qualitative or quantitative change in an oncogene (see @entity6471 for review). In the second, discovered in @entity5 , a primary mutation occurs which is recessive at the cellular level to the normal allele. The growth of a @entity5 ensues only after a secondary change, such as chromosome loss or mitotic recombination, eliminates the normal allele, thereby unmasking the altered allele. Because its effect is recessive, the primary mutation may also occur and be transmitted in the germ line, resulting in a familial pattern for the disease. In familial cases, independent @entity5 are common, since the @entity5 result from a single event--loss of the normal genes--which can occur in any cell. This contrasts with non-familial (sporadic) cases where @entity5 result from the infrequent occurrence of two rare events within the same cell. By a molecular genetic approach we have now shown that @entity5513 , one of the most common @entity5 of the @entity1 nervous system, is specifically associated with loss of genes on @entity1 chromosome 22 and may result from the mechanism of tumorigenesis discovered in @entity5 . This finding might provide a clue to the chromosomal location of the defective gene in @entity8605 , an @entity74 with the hallmark of bilateral @entity5513 . In view of the frequent occurrence of @entity1653 in @entity1 with @entity8605 and the association of @entity1653 with @entity393 previously reported in cytogenetic studies, we suggest that a common event underlies tumorigenesis in @entity5513 and @entity1653 .

title: Loss of genes on chromosome 22 in tumorigenesis of XXXX @entity5513 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'man']

entities_list: @entity5513 :: ('MESH:D009464', 'Disease') :: ['acoustic neuromas', 'acoustic neuroma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['embryonal tumours', 'solitary tumours', 'bilateral tumours', 'tumours', 'tumour']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningioma', 'meningiomas']

entities_list: @entity8605 :: ('MESH:D016518', 'Disease') :: ['bilateral acoustic neurofibromatosis']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['autosomal dominant disorder']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['loss of chromosome 22']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: @entity3840 ( @entity3840 ) is a key enzyme involved in the conversion of @entity1426 into @entity2918 . @entity3840 is mainly induced at sites of @entity32 in response to proinflammatory cytokines such as interleukin-1a/b, interferon-y and @entity5 @entity39 factor-a produced by inflammatory cells. AIM: The aim of this study was to investigate the possible modulating effect of the functional @entity3840 polymorphisms @entity17529 and @entity17530 on the risk for development of @entity29 ( @entity29 ) in a Dutch population. METHODS: Genomic DNA of 525 @entity1 with @entity30 ( @entity30 ), 211 @entity1 with @entity31 ( @entity31 ) and 973 healthy controls was genotyped for the @entity17529 ( @entity17531 ) and @entity17530 ( @entity17532 ) polymorphisms. Distribution of genotypes in @entity1 and controls were compared and genotype-phenotype interactions were investigated. RESULTS: The genotype distribution of the @entity17529 polymorphism was not different between the @entity1 with @entity30 or @entity31 and the control group. The -765GG genotype was more prevalent in @entity30 @entity1 compared to controls with an OR of 1.33 (95%CI 1.04-1.69, p<0.05). The -765GC and -765CC genotype carriers showed a tendency to be less frequent in @entity1 with @entity30 compared to controls, with ORs of 0.78 (95%CI: 0.61-1.00) and 0.49 (95%CI 0.22-1.08), respectively. Combining homozygous and heterozygous @entity1 with the -765C allele showed a reduced risk for developing @entity30 , with an OR of 0.75 (95%CI: 0.59-0.96). In the context of this, the G(-1195)G(-765)/A(-1195)C(-765) diplotype was significantly less common in @entity1 with @entity30 compared to controls, with an OR of 0.62 (95%CI: 0.39-0.98). For @entity31 however, such an effect was not observed. No correlation was found between @entity3840 diplotypes and clinical characteristics of @entity29 . CONCLUSIONS: The @entity17530 polymorphism was associated with a reduced risk for developing @entity30 in a Dutch population.

title: The functional @entity17530 polymorphism of the @entity3840 gene may reduce the risk of developing XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostaglandins']

entities_list: @entity1426 :: ('MESH:D016718', 'Chemical') :: ['arachidonic acid']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"]

answer: @entity30 :: (MESH:D003424,Disease) :: ['crohn's disease']


abstract: In July 2006, an Australian tourist returning from Dubai, in the United Arab Emirates (UAE), developed @entity9556 . Her signs and symptoms included @entity221 , @entity925 , @entity10 , @entity1910 , and eschar. @entity9557 serology demonstrated a 4-fold rise in antibody titers in paired serum collections (1:512 to 1:8,192), with the sera reacting strongest against the Gilliam strain antigen. An Orientia species was isolated by the in vitro culture of the @entity1 's acute blood taken prior to antibiotic treatment. The gene sequencing of the 16S rRNA gene (rrs), partial 56-kDa gene, and the full open reading frame 47-kDa gene was performed, and comparisons of this new Orientia sp. isolate to previously characterized strains demonstrated significant sequence diversity. The closest homology to the rrs sequence of the new Orientia sp. isolate was with three strains of @entity22449 , Kato, and Karp), with a @entity377 sequence similarity of 98.5%. The closest homology to the 47-kDa gene sequence was with @entity9557 Gilliam, with a @entity377 similarity of 82.3%, while the closest homology to the 56-kDa gene sequence was with @entity9557 TA686, with a @entity377 similarity of 53.1%. The molecular divergence and geographically unique origin lead us to believe that this organism should be considered a novel species. Therefore, we have proposed the name "Orientia chuto," and the prototype strain of this species is strain Dubai, named after the location in which the @entity1 was infected.

title: Isolation of a novel Orientia species (O. chuto sp. nov.) from a XXXX infected in Dubai.

entities_list: @entity9556 :: ('MESH:D012612', 'Disease') :: ['acute scrub typhus']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity9557 :: ('784', 'Species') :: ['O. tsutsugamushi strain', 'Orientia tsutsugamushi']

entities_list: @entity22449 :: ('334380', 'Species') :: ['O. tsutsugamushi (Ikeda']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: The aim of this study was to determine the prevalence of platelet autoantibodies ( @entity3880 ) in @entity1 with @entity1252 ( @entity1252 ) and its correlation with clinical and other laboratory manifestations of the disease, as well as to evaluate the influence of platelet count and disease activity on the result of the test for @entity3880 . Ninety @entity1252 @entity1 , 29 with @entity882 , were evaluated. The presence of @entity3880 was determined using the direct and indirect platelet suspension immunofluorescence test. A total of 166 @entity3880 determinations were performed in the 90 @entity1 upon entry into the study. Fifty-six of the 90 @entity1 (62%) with @entity1252 were positive for @entity3880 . There were no statistically significant correlations between the presence of @entity3880 and the different disease manifestations except for @entity882 (P = 0.0005). The presence of @entity3880 in the same @entity1 was significantly associated with current @entity882 and disease activity. It was concluded that the prevalence of @entity3880 in @entity1252 @entity1 is high. All @entity1252 @entity1 with @entity882 had @entity3880 , although some @entity1 with @entity3880 had a normal platelet count. The presence of @entity3880 in @entity1252 @entity1 is not synonymous with @entity882 but should instead be regarded as one of the @entity156 which may develop in these @entity1 .

title: High prevalence of platelet autoantibodies in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus']

entities_list: @entity156 :: ('MESH:D000015', 'Disease') :: ['multiple serological abnormalities']

answer: @entity1252 :: (MESH:D008180,Disease) :: ['systemic lupus erythematosus']


abstract: AIMS: Long-term data on the durability of currently available transcatheter heart valves are limited. We sought to assess four-year clinical and echocardiographic outcomes in @entity1 undergoing @entity886 ( @entity886 ) with the CoreValve prosthesis. METHODS AND RESULTS: Between June 2007 and February 2014, 450 consecutive @entity1 with symptomatic severe @entity472 underwent @entity886 in our institution. For the purposes of this study, we included only those @entity1 undergoing successful @entity886 with the CoreValve prosthesis who had a minimum follow-up of four years (n=125). Survival rates at one, two, three and four years were 83.2, 76.8, 73.6 and 66.3%, respectively. @entity337 was a common finding after the procedure, especially due to @entity338 ( @entity338 ), which was observed in the majority of @entity1 (71.5%), mostly mild (52.0%). Progression from mild acute @entity338 to moderate @entity338 at four-year follow-up was reported in three @entity1 . No cases of severe @entity338 were observed. @entity712 was reported in four @entity1 (3.2%). CONCLUSIONS: Our study demonstrates that favourable outcomes after successful @entity886 are associated with sustained clinical and functional cardiovascular bene   ts up to four-year follow-up. Signs of moderate @entity712 are present only in a small percentage of @entity1 .

title: Four-year durability of clinical and haemodynamic outcomes of XXXX with the self-expanding CoreValve.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['prosthetic valve failure', 'Prosthetic valve failure']

entities_list: @entity886 :: ('MESH:C563178', 'Disease') :: ['TAVI', 'transcatheter aortic valve implantation']

entities_list: @entity338 :: ('MESH:D011665', 'Disease') :: ['PVR', 'paravalvular regurgitation']

entities_list: @entity337 :: ('MESH:D001022', 'Disease') :: ['Aortic regurgitation']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['aortic stenosis']

answer: @entity886 :: (MESH:C563178,Disease) :: ['transcatheter aortic valve implantation']


abstract: STUDY OBJECTIVE: To evaluate the efficacy of IM @entity6058 versus that of oral @entity5018 in acute @entity4512 . DESIGN: Randomized, prospective, double-blind clinical trial. SETTING: Urban teaching emergency department with an annual census of 43,000. @entity1 : Convenience sample of 82 @entity1 aged 18 to 70 years with acute @entity4512 due to @entity130 . INTERVENTIONS: Forty-two subjects each received 60 mg @entity6058 by IM injection and ingested a placebo capsule. Forty subjects each ingested 800 mg @entity5018 and received a placebo (saline) IM injection. @entity158 was evaluated with a 100-mm visual analog scale at baseline and 15, 30, 45, 60, 75, 90, and 120 minutes after dosing. The prevalence of side effects was elicited in each @entity1 . RESULTS: Mean @entity158 scores improved in each group during the course of the study but did not significantly differ between groups at baseline or at any subsequent interval. The numbers of dropouts due to inadequate analgesia and prevalence of side effects in the two groups did not differ significantly. CONCLUSION: IM @entity6058 and oral @entity5018 provide comparable analgesia in @entity2613 @entity1 with acute @entity4512 .

title: Intramuscular @entity6058 versus oral XXXX in acute @entity4512 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PARTICIPANTS']

entities_list: @entity4512 :: ('MESH:D059352', 'Disease') :: ['musculoskeletal pain']

entities_list: @entity5018 :: ('MESH:D007052', 'Chemical') :: ['ibuprofen']

entities_list: @entity6058 :: ('MESH:D020910', 'Chemical') :: ['ketorolac']

answer: @entity5018 :: (MESH:D007052,Chemical) :: ['ibuprofen']


abstract: IMPORTANCE: Local and generalized @entity56 following laser tattoo removal have been documented, but are rare. To our knowledge, this is the fourth documented case of widespread @entity203 following laser tattoo removal treatment. Unlike previously documented cases, this @entity1 's reaction was found to be associated with @entity6701 within the tattoo and her symptoms were recalcitrant to medical therapy. OBSERVATIONS: A 46-year-old female experienced diffuse @entity11782 , erythema, and @entity111 following multiple laser tattoo removal treatments with an Nd:YAG laser. The @entity56 was recalcitrant to increasing doses of @entity8610 and @entity288 . The tattoo was finally surgically excised. The excised tissue was analyzed by scanning electron microscopy and energy-dispersive X- @entity16039 analysis and contained high levels of @entity6701 . Two weeks following the excision, and without the use of medical therapy, the @entity1 had complete resolution of her generalized @entity110 . CONCLUSIONS: Ours is the first documented case of a diffuse urticarial reaction following laser tattoo removal treatments that shows a strong association to @entity6701 within the tattoo pigment. Herein, we describe a novel surgical approach to treat recalcitrant generalized @entity56 to tattoo pigment.

title: Diffuse Urticarial Reaction Associated with XXXX Following Laser Tattoo Removal Treatments.

entities_list: @entity11782 :: ('MESH:C535817', 'Disease') :: ['urticarial plaques']

entities_list: @entity8610 :: ('MESH:D006633', 'Chemical') :: ['antihistamines']

entities_list: @entity203 :: ('MESH:D003875', 'Disease') :: ['urticarial eruptions']

entities_list: @entity111 :: ('MESH:D011537', 'Disease') :: ['pruritis']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['systemic allergic reaction', 'allergic reaction', 'allergic reactions']

entities_list: @entity6701 :: ('MESH:C009495', 'Chemical') :: ['titanium dioxide']

entities_list: @entity110 :: ('MESH:D014581', 'Disease') :: ['urticaria']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity6701 :: (MESH:C009495,Chemical) :: ['Titanium Dioxide']


abstract: OBJECTIVE: To estimate the prevalence of lumbar internal disc disruption, zygapohyseal joint @entity158 , @entity158 , and soft tissue irritation by fusion hardware in post-fusion @entity1643 @entity1 compared with non-fused @entity1 utilizing diagnostic spinal procedures. DESIGN: Retrospective chart review. SETTING: University spine center. @entity1 SAMPLE: @entity1 presenting to a community-based, multidisciplinary, academic spine center (65.9% female, mean age 54.4 years, median @entity158 duration 12 months). INTERVENTIONS: Charts of consecutive @entity1643 cases completing diagnostic spinal procedures including provocation discography and zygapohyseal joint, sacroiliac joint, and fusion hardware blockade were retrospectively reviewed. OUTCOME MEASURES: Based on the results of discography and/or diagnostic blockades, subjects were classified with internal disc disruption, zygapohyseal joint @entity158 , @entity158 , or fusion hardware related @entity158 . RESULTS: The diagnoses of 28 fusion cases identified from 170 @entity1643 @entity1 undergoing diagnostic procedures included 12 with @entity158 , seven with internal disc disruption, five with zygapohyseal joint @entity158 , and four due to soft tissue irritation from fusion hardware. No significant differences were noted in zygapohyseal joint mediated @entity158 with and without fusion history. Mean ages of @entity1 were similar with and without fusion history for cases diagnosed as internal disc disruption. CONCLUSION: In @entity1 ' recalcitrant to non-interventional care, the sacroiliac joint is the most likely source of @entity1643 after lumbar fusion followed by internal disc disruption, zygapohyseal joint @entity158 , and soft tissue irritation due to fusion hardware. @entity158 is more common after fusion, while internal disc disruption is more common in non-fusion @entity1 .

title: Etiology of @entity1643 in XXXX having undergone lumbar fusion.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENT']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['low back pain']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['sacroiliac joint pain', 'Sacroiliac joint pain', 'pain']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: AIM: Eukaryotic translation initiation factors 3a ( @entity5446 ) is involved in regulating cell cycle, cell division, growth and differentiation. Previous studies suggest a role of @entity5446 on @entity82 and cellular proliferation and differentiation of fibroblasts. The present study aims to investigate the role of @entity5446 on @entity519 -induced @entity4266 ( @entity4266 ) remodeling and underlying mechanism. MAIN METHODS: @entity4266 remodeling was induced by @entity519 (10% @entity3612 , 3weeks) in @entity35 . Primary cardiac fibroblasts were cultured in vitro and their proliferation was investigated by MTS and EdU incorporation method. @entity5446 knockdown was conducted by @entity5446 siRNA. The expression/level of @entity1810 , @entity5446 , @entity5447 and a-SMA, collagen-I, collagen-III, ANP and BNP were analyzed by ELISA, real-time PCR or Western blot. KEY FINDINGS: The expression of @entity5446 was obviously increased in right ventricle of @entity4266 remodeling @entity35 accompanied by up-regulation of a-SMA and collagens. In cultured cardiac fibroblasts, application of exogenous @entity1810 -induced cellular proliferation and differentiation concomitantly with up-regulation of @entity5446 expression and down-regulation of @entity5447 expression. The effects of @entity1810 -induced proliferation and up-regulation of a-SMA and collagen in cardiac fibroblasts were abolished by @entity5446 siRNA. @entity5446 siRNA reversed @entity1810 induced down-regulation of @entity5447 expression. SIGNIFICANCE: The @entity5446 plays a crucial role in @entity519 -induced @entity4266 remodeling by regulating @entity1810 -induced proliferation and differentiation of cardiac fibroblasts, which is mediated via @entity5446 / @entity5447 pathway.

title: Role of eukaryotic translation initiation factors 3a in @entity519 -induced XXXX remodeling of @entity35 .

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis disease']

entities_list: @entity4266 :: ('MESH:D018497', 'Disease') :: ['RV', 'right ventricular']

answer: @entity4266 :: (MESH:D018497,Disease) :: ['right ventricular']


abstract: Increased levels of @entity14662 ( @entity21920 ) in the models of @entity295 , @entity3126 , and @entity649 ( @entity649 ) suggest its potential role in the modulation of @entity647 . We have recently described @entity21920 -protective effects against thrombin-induced @entity409 in pulmonary endothelial cells (EC). The current study examined involvement of the Rac effector p21-activated kinase ( @entity21921 ) in @entity21920 -protective effects in the model of lung vascular permeability induced by bacterial wall @entity558 . C57BL/6J @entity19 or @entity21920 knockout @entity19 ( @entity14662 (-/-)) were treated with @entity558 (0.63 mg/kg intratracheal) with or without @entity21920 (2  g/kg iv). @entity651 was monitored by measurements of bronchoalveolar lavage protein content, cell count, @entity5934 , and lung histology. Endothelial barrier properties were assessed by morphological analysis and measurements of transendothelial electrical resistance. @entity21920 treatment stimulated Rac-dependent @entity21921 phosphorylation, attenuated endothelial permeability caused by @entity558 , @entity637 , and @entity777 , decreased @entity558 -induced cell and protein accumulation in bronchoalveolar lavage fluid, and suppressed @entity5934 in the @entity19 model of @entity647 . More severe @entity558 -induced @entity651 and vascular leak were observed in @entity21920 knockout @entity19 . In rescue experiments, @entity21920 injection significantly reduced @entity651 in @entity14662 (-/-) @entity19 caused by @entity558 . Molecular inhibition of @entity21921 suppressed the protective effects of @entity21920 treatment against @entity558 -induced @entity651 and endothelial @entity409 . This study shows that the protective effects of @entity21920 against @entity558 -induced vascular leak are mediated at least in part by @entity21921 -dependent signaling leading to EC barrier enhancement. Our data suggest a direct role for @entity21920 in endothelial barrier regulation via modulation of small GTPase signaling.

title: @entity14662 attenuates XXXX -induced lung vascular leak: role of @entity21921 .

entities_list: @entity14662 :: ('230899(Tax:10090)', 'Gene') :: ['atrial natriuretic peptide', 'Nppa']

entities_list: @entity3126 :: ('MESH:D011654', 'Disease') :: ['pulmonary edema']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['ARDS', 'acute respiratory distress syndrome']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['barrier dysfunction']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['Lung injury', 'lung injury']

entities_list: @entity5934 :: ('MESH:C536380', 'Disease') :: ['Evans blue extravasation']

entities_list: @entity647 :: ('MESH:D055371', 'Disease') :: ['acute lung injury']

answer: @entity558 :: (MESH:C536528,Disease) :: ['LPS']


abstract: Toll-like receptors (TLRs) have been shown to play crucial role in the recognition of unicellular pathogens. We have shown the expression of three TLRs on @entity5 cells of @entity1 @entity189 by means of immunohistochemistry. In the current study we searched presence of @entity11709 -10 on protein and molecular level in @entity189 cell lines and the impact of respective TLR ligands on TLR expression. @entity189 cell lines have been used. Cell were subjected to immunocytochemistry. RNA isolated from the cells was tested by RT-PCR. Cells were cultured in the presence of respective TLR ligands. Cells than were harvested and subjected to flow cytometry, using anti @entity11709 -10 Moabs. The cells were evaluated of membrane and cytoplasmic cell staining. TLR reactivity varied in individual cell lines. RT-PCR allowed to show mRNA for all TLRs tested. After short-term cell culture each cell line exhibited distinct pattern of expression of TLRs following interaction with respective ligand. Cytoplasmic TLR staining had usually higher MFI value than membrane one, but after culture with ligand it became reversed. TLRs 7 and 9 showed highest expression in the majority of @entity5 cells tested. In conclusion, @entity189 cell lines exhibit rather universal expression of TLRs, both on protein and molecular level. Culture of TLR expressing @entity5 cells with ligands points out for potential reactivity of @entity5 cells with TLR agonists, what may have therapeutic implications.

title: TLR receptors in XXXX - immunophenotypic, molecular and functional studies.

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['laryngeal carcinoma', 'Larynx carcinoma', 'larynx carcinoma']

answer: @entity189 :: (MESH:D002277,Disease) :: ['laryngeal carcinoma']


abstract: PURPOSE: Genitography has traditionally been an imperative part of radiographic evaluation in females born with @entity774 before surgical reconstruction. We evaluated the role of preoperative genitogram in surgical reconstruction planning and how it correlates with intraoperative findings. MATERIALS AND METHODS: We retrospectively reviewed the records of 40 @entity1 with @entity774 who underwent feminizing genitoplasty at our institution between 2003 and 2009. Preoperative genitogram findings were recorded and correlated with operative findings. RESULTS: A total of 42 preoperative genitograms were available for review in 40 @entity1 with @entity774 who underwent feminizing genitoplasty. Genitography revealed complete anatomy of the urogenital sinus in 30 cases (72%) while bladder filling alone was present in 9 (21%) and vaginal filling was noted in 2 (5%). The urogenital sinus could not be catheterized in 1 @entity1 (2%). @entity3025 was identified in 6 @entity1 (15%) with a mean grade of 2. Vaginoplasty was done with a flap technique in 37 @entity1 (more than 90%) while the remaining 3 underwent pull-through vaginoplasty. In no case did genitogram reveal anatomy that was not visible via endoscopy or at reconstruction. The vaginoplasty technique was based on endoscopic and intraoperative findings, and not on genitogram. CONCLUSIONS: Genitography during preoperative evaluation in females with @entity774 undergoing feminizing genitoplasty did not reveal urogenital sinus anatomy completely in 25% of the @entity1 in our series. Preoperative genitogram did not influence the surgical approach. Its value as preoperative imaging in @entity1 with @entity774 may be limited.

title: Does preoperative genitography in XXXX cases affect surgical approach to feminizing genitoplasty?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3025 :: ('MESH:D014718', 'Disease') :: ['Vesicoureteral reflux']

entities_list: @entity774 :: ('MESH:D000312', 'Disease') :: ['congenital adrenal hyperplasia']

answer: @entity774 :: (MESH:D000312,Disease) :: ['congenital adrenal hyperplasia']


abstract: OBJECTIVE: Despite significant efforts at a primary care level, at least 35% of @entity1 with @entity6 fail to meet health targets. It is assumed that these poor results are a consequence of the @entity1 not understanding their disease or not caring. This study seeks to understand what really lies behind poor control. DESIGN SETTING AND @entity1 : A qualitative study using semistructured interviews was conducted in a primary care setting in rural Western Australia. @entity1 living with @entity6 for at least two years were specifically selected on the basis of whether they had either 'good' (HbA1c < 7%) or 'poor' (HbA1c > 8%) control. RESULTS: Interviews revealed that @entity1 understood only too well their disease and their responsibilities. Frequently, either they did not choose to make @entity6 a priority in their lives or were unable to make appropriate lifestyle changes which were demanded for good blood sugar control. Their life/social stresses often influenced their @entity413 control. CONCLUSION: Poor control in our study was not related to lack of knowledge but more to how @entity6 was prioritised in their lives. Attention to the @entity1 ' priorities is required to accomplish improved glycaemic control.

title: It's not just about the HbA1c, Doc! Understanding the psychosocial is also important in managing XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PARTICIPANTS', 'people', 'People']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: More than 90% of all @entity2828 Family of @entity5 (ESFT) exhibit specific chromosomal rearrangements between the @entity12726 gene on chromosome 22 and various members of the ETS gene family of transcription factors. The gene fusion type and other secondary genetic alterations, mainly involving cell cycle regulators, have been shown to be of prognostic relevance in ESFT. However, no conclusive results have been reported. We analyzed the clinicopathological significance of relevant cell cycle regulators in genetically confirmed ESFT. A total of 324 cases were analyzed for the immunohistochemical expression of @entity876 , @entity994 ( @entity994 / @entity994 ) , @entity5438 ( @entity13525 ) and Ki67 and the chromosomal alterations of the @entity876 and 9p21 locus by fluorescent in situ hybridization. We observed that expression of @entity876 (p = 0.025), @entity994 ( @entity994 / @entity994 ) (p = 0.015) and @entity5438 ( @entity13525 ) (p = 0.013) was higher in disseminated than in localized disease. Furthermore, a cohort of 217 @entity1 with localized disease was considered for studying the prognosis involvement of these factors on @entity1 follow-up. The median follow-up was 39 months (range: 0.17-452) with an overall survival (OS) of 55%. Ki67 was expressed in 34% of cases and constituted an independent prognostic factor for progression free survival and OS independently of the type of treatment [hazard ratio of 2.0 (95% CI: 1.3-3.1; p = 0.003) and 1.9 (95% IC: 1.3-2.9; p = 0.007) for progression free survival and OS, respectively, being especially relevant in the group of @entity1 which incorporated radiotherapy in their regimen schedules. In conclusion, this study demonstrates that Ki67 expression constitutes a valuable indicator of poor prognosis in localized ESFT.

title: Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed XXXX family of @entity5 .

entities_list: @entity2828 :: ('MESH:D012512', 'Disease') :: ["Ewing's Sarcoma"]

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumors']

answer: @entity2828 :: (MESH:D012512,Disease) :: ['Ewing's sarcoma']


abstract: A young Caucasian @entity1 developed bilateral @entity1150 ( @entity1150 ) while taking the oral contraceptive (OC) in 1984. After a 9-month period of longterm anticoagulation therapy with @entity1229 , she experienced recurrent @entity1150 2 weeks following discontinuation of anticoagulation. She was then maintained with @entity1229 for the following 6 years. Elevated antibodies to @entity6894 (IgG aCL) were first detected in 1988. In 1990, @entity1229 was switched to aspirin and low molecular weight heparin as she wished to become pregnant. At 24 weeks she developed @entity3036 and labor was induced. During the first postpartum week she experienced loin @entity158 , associated with rapidly rising @entity1011 levels and features of a @entity1985 . An abdominal ultrasound showed bilateral @entity715 with enlarged kidneys. She was treated with continuous ambulatory peritoneal dialysis (CAPD) for 4 months and her renal function is now recovering. Our @entity1 is another example of the @entity1701 .

title: Postpartum bilateral XXXX in the @entity1701 .

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic syndrome']

entities_list: @entity1701 :: ('MESH:D016736', 'Disease') :: ['primary antiphospholipid syndrome']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thromboses', 'DVT']

entities_list: @entity3036 :: ('MESH:D004461', 'Disease') :: ['eclampsia']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['renal vein thrombosis']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']

entities_list: @entity6894 :: ('MESH:D002308', 'Chemical') :: ['cardiolipin']

answer: @entity715 :: (MESH:D013927,Disease) :: ['renal vein thrombosis']


abstract: PURPOSE: In 2007, the German Working Group "Workflow @entity5 " published 19 quality indicators with 36 quality goals for the treatment of @entity5 . We investigate whether these parameters are practicable in a specialized coloproctologic unit. @entity1 AND METHODS: We included 578 consecutive @entity1 with @entity5 who were treated in our institution from January 2000 to December 2008. @entity1 data were collected in a prospective database. Follow-up was conducted in a @entity14 clinic. Data were analyzed for the defined reference groups, and the results were compared with the quality goals. RESULTS: Median follow-up was 54.4 (range 1-116) months. We achieved 19 of the 36 defined quality goals. Among these were important parameters such as the rate of postoperative mortality (0.9%), the rate of intraoperative @entity5 perforation (2.2% for anterior resection and 8.5% for abdominoperineal excision), the 5-year local recurrence rate (5.9% stages I-III), and the 5-year overall survival rates for stages yII and II (79.9%), and stages yIII and III (60.7%) for @entity1 with microscopically negative resection margins. CONCLUSION: Most of the defined quality goals can be achieved in a specialized coloproctologic unit. The debate on quality goals has the potential to enable further improvement in the care of @entity5 @entity1 .

title: Practicability of quality goals for the treatment of XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Rectal Cancer II', 'rectal cancer', 'local tumor']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS', 'Patient']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal tumor']

answer: @entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']


abstract: Oxidized lipids initiate and modulate the inflammatory cellular events in the arterial wall and the formation of macrophage foam cells. @entity4210 mediates the cellular uptake of ox-LDL through its recognition of specific truncated @entity844 moieties and oxidized @entity2434 . Evidence has been reported that chemokine @entity6332 , rather than @entity4210 , is the main scavenger receptor in @entity1 podocytes mediating the uptake of ox-LDL. Ox-LDL induces loss of @entity6333 expression from cultured podocytes. It has been recently shown that @entity6333 once phosphorilated associates with PI3K and stimulates the Akt dependent signaling. This pathway plays a critical role in @entity6333 -actin-dependent cytoskeleton activation and remodeling, in the control of protein trafficking and in podocyte survival. An enhanced FFA uptake by podocytes is mediated by increased C36 scavenger receptor expression, together with a decrease of betaoxidation and in turn intracellular lipid accumulation. Accumulated FFA that is trapped into the mitochondrial matrix leads to mitochondrial ROS production, lipid peroxidation and @entity2383 . A disturbed transport and oxidation of @entity6334 , paralleled by an impaired antioxidant response, damages podocyte structure and leads to @entity8 in early stages of @entity3450 . Increased @entity412 synthesis and ox-and glycated LDL uptake by mesangial cells may also contribute to determine @entity2316 . Oxidative processes are pivotal events in @entity8 and epithelial cells exposed to ox-LDL. Notably @entity6332 are the main receptors for the uptake of ox-LDL in podocytes, whereas @entity4210 plays this role in tubular renal cells. In overt type 2 @entity6 Ox-LDL and FFA damage podocyte function, SD-podocyte structure and tubulointerstitial tissue, at least partially, through different pathogenetic mechanisms. Further studies are needed to investigate the role of Ox-LDL and FFA on @entity8 in @entity28 , insulin resistant @entity1 before the development of @entity6 . The aim of the present review is to briefly elucidate the patterns of systemic lipid metabolism and the individual effects of lipotoxicity at glomerular and tubular level in the kidney of overt type 2 @entity6 @entity1 . These findings better elucidate our knowledge of @entity2316 , beside and along with previous findings, in vivo and in vitro, on ox-LDL and FFA effects in mesangial cells.

title: Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of @entity8 and tubulointerstitial lesions in type 2 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['injury to renal tubular', 'renal complications', 'glomerulopathy']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic glomerulopathy']

entities_list: @entity2434 :: ('MESH:D010713', 'Chemical') :: ['phosphatidylcholine']

entities_list: @entity3450 :: ('MESH:D009401', 'Disease') :: ['nephrosis']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity2383 :: ('MESH:D028361', 'Disease') :: ['mitochondrial damage and dysfunction']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: Two probes previously shown to distinguish the nicotinic ACh receptor of @entity1573 @entity528 also recognize a component on the surface of @entity291 chromaffin cells in culture that displays the properties expected for the chromaffin nicotinic ACh receptor. The first probe is a monoclonal antibody, mAb 35, raised against ACh receptor from Electrophorus electric organ, and the second is an alpha-neurotoxin, Bgt 3.1, purified from @entity6840 venom. mAb 35 binds specifically to a single class of high-affinity sites on the chromaffin cells in culture. Scatchard analysis indicates a KD of 2.1 +/- 0.2 nM for the binding and a Bmax of 1.6 +/- 0.1 X 10(4) @entity19 sites per cell. The number of sites on the cells can be reduced through modulation by exposure of the cells to Bgt 3.1. The modulation can be blocked by the cholinergic ligands @entity2899 and @entity5402 . Long-term exposure to the agonist @entity5402 alone also reduces the number of mAb 35 binding sites. Bgt 3.1 inhibits @entity1239 -induced @entity2922 release from the cells to the same extent and with the same concentration dependence that it modulates the number of @entity19 sites on the cells. In addition, @entity19 treatment of the cells causes a specific and almost complete blockade of @entity1239 -induced @entity2922 release, apparently through a modulation of the receptor. These results indicate that the @entity291 chromaffin component recognized by mAb 35 and Bgt 3.1 is likely to be the nicotinic ACh receptor on the cells and that it has many similarities to ACh receptors on @entity1573 autonomic neurons.

title: Immunological identification of a nicotinic acetylcholine receptor on XXXX chromaffin cells.

entities_list: @entity1239 :: ('MESH:D009538', 'Chemical') :: ['nicotine']

entities_list: @entity2922 :: ('CHEBI:33567', 'Chemical') :: ['catecholamine']

entities_list: @entity6840 :: ('8616', 'Species') :: ['B. multicinctus']

entities_list: @entity2899 :: ('MESH:D014403', 'Chemical') :: ['d-tubocurarine']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['ciliary ganglion neurons']

entities_list: @entity5402 :: ('MESH:D002217', 'Chemical') :: ['carbamylcholine']

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: OBJECTIVE: We retrospectively analyzed survival, local control rate, and incidence of radiation @entity137 after radiosurgery for recurrent metastatic @entity75 whose initial @entity3 were treated with whole-brain radiotherapy. Various radiotherapeutical indices were examined to suggest predictors of radiation-related @entity51 . METHODS: In 46 @entity1 , total 100 of recurrent @entity3 (mean 2.2, ranged 1-10) were treated by CyberKnife radiosurgery at average dose of 23.1 Gy in 1 to 3 fractions. The median prior radiation dose was 32.7 Gy, the median time since radiation was 5.0 months, and the mean @entity5 volume was 12.4 cm(3). Side effects were expressed in terms of radiation therapy oncology group (RTOG) @entity2359 criteria. RESULTS: Mass reduction was observed in 30 @entity1 (65%) on MRI. After the salvage treatment, one-year progression-free survival rate was 57% and median survival was 10 months. Age (<60 years) and @entity5 volume affected survival rate (p=0.03, each). Acute (</=1 month) @entity137 was observed in 22% of @entity1 , subacute and chronic (>6 months) @entity137 occurred in 21%, respectively. Less acute @entity137 was observed with small @entity5 (<10 cm(3), p=0.03), and less chronic @entity137 occurred at lower cumulative doses (<100 Gy, p=0.004). " @entity137 factor" (cumulative dose times @entity5 volume of <1,000 Gyxcm(3)) was a significant predictor of both acute and chronic CNS @entity137 . CONCLUSION: Salvage CyberKnife radiosurgery is effective for recurrent brain @entity3 in previously irradiated @entity1 , but careful evaluation is advised in @entity1 with large @entity5 and high cumulative radiation doses to avoid @entity137 .

title: Radiosurgery for recurrent brain XXXX after whole-brain radiotherapy : factors affecting radiation-induced @entity51 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Radiation toxicity', 'toxicities']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain lesions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological dysfunction']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: BACKGROUND: Controversy exists with regard to the impact that the different components of diagnosis delay may have on the degree of invasion and prognosis in @entity1 with @entity14 . The follow-up strategies after treatment also vary considerably. The aims of this study are: a) to determine if the symptoms-to-diagnosis interval and the treatment delay modify the survival of @entity1 with @entity14 , and b) to determine if different follow-up strategies are associated with a higher survival rate. METHODS/DESIGN: Multi-centre study with prospective follow-up in five regions in Spain (Galicia, Balearic Islands, Catalonia, Arag  n and Valencia) during the period 2010-2012. Incident cases are included with anatomopathological confirmation of @entity14 (International Classification of Diseases 9th revision codes 153-154) that formed a part of a previous study (n = 953).At the time of diagnosis, each @entity1 was given a structured interview. Their clinical records will be reviewed during the follow-up period in order to obtain information on the explorations and tests carried out after treatment, and the progress of these @entity1 .Symptoms-to-diagnosis interval is defined as the time calculated from the diagnosis of @entity5 and the first symptoms attributed to @entity5 . Treatment delay is defined as the time elapsed between diagnosis and treatment. In non-metastatic @entity1 treated with curative intention, information will be obtained during the follow-up period on consultations performed in the digestive, surgery and oncology departments, as well as the endoscopies, @entity5 markers and imaging procedures carried out.Local recurrence, development of @entity3 in the follow-up, appearance of a new @entity5 and mortality will be included as outcome variables.Actuarial survival analysis with Kaplan-Meier curves, Cox regression and competitive risk survival analysis will be performed. DISCUSSION: This study will make it possible to verify if the different components of delay have an impact on survival rate in @entity694 and @entity5 . In consequence, this multi-centre study will be able to detect the variability present in the follow-up of @entity1 with @entity14 , and if this variability modifies the prognosis. Ideally, this study could determine which follow-up strategies are associated with a better prognosis in @entity14 .

title: Diagnosis delay and follow-up strategies in XXXX . Prognosis implications: a study protocol.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'rectal cancer', 'tumour']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: Coxsackievirus B (CB) 4 causes transmural @entity2401 in suckling @entity19 with ensuing development of focal ventricular thinning or @entity439 . We studied whether subsequent @entity281 with another cardiotropic virus influences the expression of CB4 disease. @entity281 was established in 2-day-old @entity2659 @entity19 by intraperitoneal (IP) inoculation. Three weeks later, surviving animals were randomized to receive CB3 or saline IP. They were then killed over a 45-day period. CB4 neutralizing antibody (NA) titres were comparable in both groups (31 +/- 23 vs 37 +/- 19). CB3 NA were detected in CB3 infected animals only (72 +/- 86 versus 0). The incidence of @entity2401 was comparable (67.4% vs 55.2%). The indices of histopathological changes (assessed according to a semiquantitative grading scale from 0-4) were greater among CB3 recipients on day 9 post CB3 challenge (1.38 +/- 0.43 vs 0.46 +/- 0.4, P < 0.001) and to a lesser extent, on day 13 (0.56 +/- 0.56 vs 0.19 +/- 0.38, P > 0.1). On days 30, and 45, these indices became similar in both groups. Focal thinning was noted on days 45 in 6/11 animals with @entity281 alone and in 0/11 @entity19 with subsequent CB3 @entity281 (P = 0.006). These findings show that CB3 @entity2401 can be expressed in @entity19 with prior CB4 disease, that sequential infections do not lead to cumulative @entity299 , and that subsequent CB3 @entity281 suppresses the formation of CB4 induced @entity439 .

title: The effect of subsequent myocardial damage on the expression of coxsackievirus B4 @entity2401 and the development of XXXX .

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'CB4 infection']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'ventricular aneurysms']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac injury']

entities_list: @entity2401 :: ('MESH:D009205', 'Disease') :: ['myocarditis']

answer: @entity439 :: (MESH:D000783,Disease) :: ['ventricular aneurysms']


abstract: Desmosomes represent a special type of the plaque-bearing adhering junctions, characteristic of certain pathways of cell differentiation, which compositionally are not identical in the various kinds of desmosome-forming cells. While all desmosomes contain the cytoplasmic plaque proteins desmoplakin I and plakoglobin, they can vary in their specific complement of desmosomal cadherins and by the presence of additional plaque proteins. We have raised monoclonal antibodies recognizing one such 'accessory' plaque protein, the cytokeratin-binding, basic protein @entity14892 , originally introduced as ' @entity14892 ' or 'polypeptide D6', which is an abundant desmosomal component in certain epithelia. Using such antibodies, we have isolated cDNA clones encoding the @entity291 and the @entity1 protein and determined their complete @entity535 sequences. The mRNAs, which on Northern blot tests appear as two bands corresponding to approximately 4 and 2.4 kb ( @entity291 ) or 5 and 2.6 kb ( @entity1 ), code for 727 @entity1522 (calculated mol. wt. 80,180; IEP 9.25) in @entity291 and 726 @entity1522 (mol. wt. 80,496; IEP 9.34) in @entity1 plakophilin. Sequence analyses have revealed the presence of 9.2 repeated units of the arm-motif sequence, confirming our previous conclusion that this protein is a member of a larger family of proteins including, inter alia, several membrane-associated plaque proteins such as vertebrate plakoglobin and @entity19280 as well as the product of the @entity19280 gene of @entity238 . The plakophilin antibodies and cDNA probes have also allowed us to examine its synthesis in various tissues and cell cultures. While we confirm the occurrence of the protein in cytoskeletal fractions from various stratified squamous, complex, glandular duct and @entity1494 , where it can be localized to desmosomes, we have, surprisingly, also identified the protein, although at lower amounts, in cytoskeletal fractions from several cultured cell lines in which the protein has not been consistently localized to desmosomes by immunofluorescence microscopy. Examples include cultured cells derived from certain simple epithelia such as the kidney-derived line MDBK and cultured @entity291 lens cells. We have also found that, in all @entity14892 -positive cells examined, a pool of diffusible ('soluble') cytoplasmic plakophilin exists, including cell lines such as @entity1 @entity189 MCF-7 cells in which this soluble plakophilin seems to be the only detectable form. In addition, we have identified some soluble proteins conspicuously cross-reacting with @entity14892 . Possible functions of plakophilin and its potential value as a marker for specific states of cell differentiation are discussed, particularly with respect to @entity5 diagnosis.

title: Cell type-specific desmosomal plaque proteins of the plakoglobin family: XXXX ( @entity14892 ).

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder epithelia']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['mammary carcinoma']

entities_list: @entity14892 :: ('5317', 'Gene') :: ['band 6 protein', 'plakophilin 1']

entities_list: @entity238 :: ('7227', 'Species') :: ['Drosophila']

answer: @entity14892 :: (5317,Gene) :: ['plakophilin 1']


abstract: BACKGROUND: The optimal treatment of @entity420 is unknown. METHODS: The records of 491 @entity1 with @entity420 diagnosis between 1970 and 2005 were reviewed for @entity1 and @entity5 characteristics, treatment effects, and survival. RESULTS: The median age at diagnosis was 62 years. The most common @entity5 locations were the duodenum (57%), jejunum (29%), and ileum (10%). The median overall survival was 20.1 months, with a 5-year overall survival of 26%. Greater age, male sex, higher stage and grade, @entity66 after resection, and a lymph node ratio of 50% or greater predicted decreased overall survival in univariate analysis. Age and stage were predictive of survival in multivariate analysis. The overall survival with metastatic disease was poor. Adjuvant therapy was not associated with longer overall survival (P = .44). CONCLUSIONS: The prognosis of @entity1 with @entity420 is poor. Complete resection provides the only means of cure, and the role for adjuvant therapy remains uncertain.

title: A single-institution experience with 491 cases of XXXX .

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['small bowel adenocarcinoma']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

answer: @entity420 :: (MESH:D000230,Disease) :: ['small bowel adenocarcinoma']


abstract: BACKGROUND: @entity308 in @entity454 @entity1 is detrimental to quality of life, and is also associated with adverse clinical outcomes. The aim of this study was to examine whether @entity308 symptoms in 'incident dialysis' @entity1 predicted survival. METHODS: One hundred and sixty incident haemodialysis and peritoneal dialysis @entity1 completed a self-report @entity308 questionnaire (Beck @entity308 Inventory-II, BDI) at a point soon after dialysis initiation. Over the study period (May 2007-December 2009), @entity1 were followed up with all-cause mortality recorded as the end point. RESULTS: The median follow-up time for the cohort was 511 days (min 47 days and max 1027 days). There were 27 deaths (16.9%). @entity308 symptoms were evaluated both as a continuous variable and using a defined cut-off for @entity308 @entity1 (BDI >=  16). In a Cox proportional hazards model, adjusted for several covariates including albumin and extra renal comorbidity, @entity308 score was an independent predictor of mortality (HR = 1.07, 95% CI 1.02-1.11, P = 0.002). In an additional adjusted model, a BDI score >=  16 was associated with a 2.7 times increase in the hazard for @entity204 (HR = 2.7, 95% CI 1.06-6.8, P = 0.037). CONCLUSIONS: The severity of @entity308 symptoms following the start of dialysis treatment is an independent predictor of survival. Further studies will be required to determine whether the treatment of @entity308 would alter health-related outcomes, including survival.

title: An association between depressive symptoms and survival in incident dialysis XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depressed', 'depression']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: There are various drugs tried for relieving @entity158 associated with radiation-induced @entity33 . This paper aims to study role of honey in relieving @entity158 due to radiation induced @entity33 in @entity135 @entity1 receiving concomitant chemoradiation. MATERIALS AND METHODS: A randomized controlled trial on 78 subjects (40 in test group and 38 in control group) was undertaken to study the analgesic effect of honey, but the analysis of 69 @entity1 was done as nine @entity1 (four in test and five in control group) were lost to follow-up or left treatment in between the study. All @entity1 were advised to do salt-soda and @entity3310 mouth gargles, alternatively every 3 hours. Test group @entity1 additionally received 20 ml honey three times a day during the entire course of radiation treatment and 3 months following @entity1161 ( @entity1161 ). RESULTS: Honey significantly reduced the severity of @entity33 associated @entity158 and resulted in lesser treatment gaps and a decrease in overall radiotherapy treatment duration. None of the test group and majority of controls (51.5%) had severe @entity158 score during the 7(th) week of @entity1161 . The same pattern was seen in the post- @entity1161 period. Mean @entity158 score was significantly different in both groups during all weeks during and upto 6 weeks post- @entity1161 (mean score of 3.08 and 6.54 for test and control respectively at 7(th) week @entity1161 , P < 0.001). CONCLUSION: Honey being a cheap, palatable, and natural medicament can be used for decreasing @entity158 associated with radiation-induced @entity33 in @entity5 @entity1 .

title: A Randomized Controlled Trial Evaluating the Role of Honey in Reducing @entity158 Due to Radiation Induced @entity33 in @entity135 XXXX .

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer']

entities_list: @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT']

entities_list: @entity3310 :: ('MESH:D001591', 'Chemical') :: ['benzydamine']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: In order to determine the effects of @entity134 administration on the metabolic response to isolated closed- @entity542 , a longitudinal study was performed. Metabolic indices were prospectively evaluated for the first 5 days postinjury in six @entity1 who received @entity230 and 10 @entity1 who did not. @entity1 were carefully screened to eliminate those with associated injuries as well as those with abnormalities due to @entity295 . Other than @entity134 administration, a uniform treatment regimen was used in both groups. Metabolic indices measured on postinjury Days 1, 3, and 5 were analyzed. In addition, data were compared to results in large data banks obtained both from overnight-fasted @entity1 (fasted controls) and from polytrauma victims (stressed controls). Both treatment groups were comparable with respect to age, mean Glasgow Coma Scale scores on admission and on Day 5, and initial intracranial pressure. Metabolic data indicated significantly higher levels of @entity1568 excretion and somatic protein mobilization in @entity134 -treated @entity1 than in @entity1 not receiving @entity230 . In both groups, @entity413 levels, the @entity880 / @entity2388 ratio, and branched-chain @entity535 levels (all metabolic indices that correlate well with level of stress) initially corresponded to values for stressed controls. By Day 5, values for these variables were similar to fasted controls for the group not receiving @entity230 . In @entity1 receiving @entity230 , however, the data remained similar to those for stressed controls. It is concluded that @entity230 prolong the metabolic abnormalities associated with the initial phase of @entity542 . In view of inconclusive data regarding benefit from @entity134 administration, serious questions must be raised regarding the use of these catabolic agents in this setting.

title: Physiological and metabolic response to isolated closed- XXXX . Part 2: Effects of @entity230 on metabolism. Potentiation of protein wasting and abnormalities of substrate utilization.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity2388 :: ('MESH:D019289', 'Chemical') :: ['pyruvate']

answer: @entity542 :: (MESH:D006259,Disease) :: ['head injury']


abstract: Transport of free @entity1718 ( @entity6334 ) across the adipocyte plasma membrane is critical for maintaining homeostasis. To determine the membrane's role in regulating transport we describe here the first measurements of the intracellular (unbound) @entity6334 concentration ([ @entity6334 (i)]) and their use in monitoring transport of @entity6334 across 3T3F442A adipocytes. [ @entity6334 (i)] was measured by microinjecting cells with ADIFAB, a fluorescently labeled @entity844 -binding protein that is used to measure unbound @entity6334 levels. We used ratio fluorescence microscopy of intracellular ADIFAB to image unbound @entity6334 levels and determined the time course of [ @entity6334 (i)] in response to changing the extracellular unbound @entity6334 concentration ([ @entity6334 (o)]). [ @entity6334 (o)] was clamped at defined levels using complexes of @entity6334 and bovine serum albumin. We show that @entity6334 influx is slow, requiring about 300 s to reach steady state (rate constant approximately 0.02 s(-1)) and saturable (K(o) approximately 200 nm). Efflux is twice as fast as influx, for zero [ @entity6334 (o)], but decreases with increasing [ @entity6334 (o)]. Surprisingly, at steady state [ @entity6334 (i)] is 2-5-fold (average 2-fold) greater than [ @entity6334 (o)] and this [ @entity6334 (i)]/[ @entity6334 (o)] gradient is abolished by depleting cellular @entity855 . Our results indicate that @entity6334 transport across adipocyte membranes is highly regulated, involving an @entity855 -driven pump and a mechanism for gating efflux that is sensitive to [ @entity6334 (o)]. These characteristics are well described by a membrane carrier model but are not consistent with @entity6334 transport across the membrane's lipid phase. We suggest that these characteristics are important in regulating circulating @entity6334 levels by the adipocyte.

title: @entity844 transport in adipocytes monitored by imaging intracellular free XXXX levels.

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

answer: @entity844 :: (CHEBI:35366,Chemical) :: ['fatty acid']


abstract: We studied the healing efficacy of @entity4444 or placebo in 23 endoscopically proven duodenal @entity1066 outpatients in a randomized, controlled, prospective, double-blind trial. There were 11 @entity1 in the @entity4444 (1200 mg daily) treatment group and 12 @entity1 in the placebo-treated group. No antacid was allowed, but a placebo antacid with no neutralizing capacity was given as needed for @entity158 . The incidence of complete endoscopic healing at 2, 4, and 6 weeks was 54%, 63%, and 72% in the @entity4444 -treated @entity1 and 8%, 50%, and 67% in the placebo-treated @entity1 . There was a statistically significant difference (P < 0.05) in complete duodenal @entity1066 between both treatment groups after 2 weeks of therapy, but there was no significant difference at the 4- and 6-week observation periods. The incidence of @entity158 relief at 2 and 4 weeks was 64% and 82% in the @entity4444 -treated @entity1 and 67% and 75% in the placebo-treated @entity1 . At 6 weeks of treatment there was no increase in the number of @entity1 with @entity158 relief in either group. There was no significant difference between the two groups in the incidence of @entity158 relief at any of the three observation periods. @entity4773 rates and duodenal @entity158 relief were compared at 2, 4, and 6 weeks. There was no statistical association between @entity1066 and @entity158 relief in the placebo treatment group at the 2-week evaluation period, but there was statistical association (P < 0.05) in the @entity4444 treatment group at 2 weeks and both treatment groups at the 4- and 6-week evaluation periods. The results of this study demonstrate that in duodenal @entity1066 out- @entity1 treated for 6 weeks: (1) @entity4444 increases the incidence of duodenal @entity1066 during the first 2 weeks of treatment; (2) more than 50% of duodenal ulcers will spontaneously heal during a 4 to 6-week observation period which is not statistically modified by @entity4444 treatment; (3) the complete relief of duodenal @entity158 is not influenced by treatment with @entity4444 when compared to placebo.

title: XXXX vs placebo in duodenal @entity1066 therapy. Six-week controlled double-blind investigation without any antacid therapy.

entities_list: @entity4444 :: ('MESH:D002927', 'Chemical') :: ['cimetidine']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer', 'ulcer healing']

entities_list: @entity4773 :: ('MESH:D004381', 'Disease') :: ['Duodenal ulcer healing']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'complete pain', 'ulcer pain']

answer: @entity4444 :: (MESH:D002927,Chemical) :: ['Cimetidine']